Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
VHIR
Menu
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
Close Menu
VHIR
Featured
Facts & Figures
Top Stories
Highlights
eCORE
Best Scientific Images
Partners and Acknowledgements
Download Summary
VHIR Annual Report 2023